Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

Market Cap	45.46B -28.2%
Revenue (ttm)	32.52B +0.3%
Net Income	4.57B -7.3%
EPS	109.69 -7.3%
Shares Out	41.63M
PE Ratio	9.96
Forward PE	10.82
Dividend	50.00 (4.52%)
Ex-Dividend Date	Mar 30, 2026

Volume	165,300
Open	1,100.00
Previous Close	1,105.00
Day's Range	1,092.00 - 1,117.00
52-Week Range	1,067.00 - 2,005.00
Beta	-0.25
Analysts	Buy
Price Target	2,340.00 (+114.29%)
Earnings Date	May 11, 2026

About TYO:2395

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1957
• Employees: 1,522
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2395

Financial Performance

In fiscal year 2026, TYO:2395's revenue was 32.52 billion, an increase of 0.35% compared to the previous year's 32.41 billion. Earnings were 4.57 billion, a decrease of -7.26%.

Analyst Summary

According to 2 analysts, the average rating for 2395 stock is "Buy." The 12-month stock price target is ¥2,340, which is an increase of 114.29% from the latest price.

Price Target

¥2,340

(114.29% upside)

Analyst Consensus: Buy